The proteomic analysis elucidated that ANXA5, GPM6A, VGF, and ACTZ could distinguish AD EVs from controls with high accuracy, thus providing novel biomarkers for AD (Muraoka et al., 2020c). Here, VGF is linked to Alzheimer disease.